Algert Global LLC Has $9.12 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Algert Global LLC raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 8.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 74,984 shares of the biotechnology company's stock after purchasing an additional 5,778 shares during the period. Algert Global LLC owned 0.08% of Sarepta Therapeutics worth $9,117,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Manchester Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics in the fourth quarter worth about $36,000. Steward Partners Investment Advisory LLC increased its holdings in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after buying an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after buying an additional 216 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wells Fargo & Company decreased their price objective on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating for the company in a report on Thursday. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday. Scotiabank lowered their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research report on Thursday, March 20th. Morgan Stanley dropped their price target on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, HC Wainwright dropped their price objective on Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $131.22.

Sarepta Therapeutics Trading Down 0.7 %

Shares of SRPT traded down $0.25 on Friday, reaching $36.27. 6,614,378 shares of the company's stock were exchanged, compared to its average volume of 1,621,069. Sarepta Therapeutics, Inc. has a 12 month low of $35.46 and a 12 month high of $173.25. The stock has a market capitalization of $3.56 billion, a P/E ratio of 29.02 and a beta of 0.85. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The business has a 50 day moving average price of $66.84 and a two-hundred day moving average price of $100.66.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period last year, the company earned $0.73 EPS. The business's revenue for the quarter was up 80.2% compared to the same quarter last year. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.